PCT was recently featured in the BioProcess International Industry Yearbook. The article by Sanjin Zvonic, Ph.D., Director of Technology and Business Development for PCT, “Managing the Challenges of Cell Therapy Product Delivery in Clinical and Commercial Settings”, discusses solutions for the unique problem of cell therapy product delivery. This includes delivery, quality control, scale, operational parameters and the effect they have on operational costs, commercial viability and marketplace acceptance. At PCT, we have successfully implemented this approach and are currently enabling it in an active clinical trial.
To read this artcle, please the Bioprocess International website, by clicking here.
*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, formerly PCT or PCT Cell Therapy Services), apceth Biopharma GmbH are all now operating under the name Minaris Regenerative Medicine. Hitachi Chemical Co., Ltd. has been renamed Showa Denko Materials Co., Ltd.
